Press releases

A live webcast and replay of the February 5 conference call will be available

CE Mark approvals are for COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN™ implantable cardioverter defibrillator (ICD)

Ruling finds the NIR® stent, formerly sold by Company, infringed one claim of a patent owned by Johnson & Johnson

Divestitures are part of ongoing efforts to simplify operating model and restore profitable growth

Company retains ownership of Pain Management business

A live webcast and replay of the January 9 session will be available

LIVIAN™ CRT-D is specifically designed to monitor heartbeats in heart failure patients and deliver small electrical impulses that may improve the heart's pumping ability

TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent

In addition to the two sales announced today, Boston Scientific has also recently announced agreements to sell its Cardiac Surgery, Vascular Surgery and Auditory businesses

The two stent systems are identical products; would be covered by the same FDA approval

A live webcast and replay of the December 5 session will be available

A live webcast and replay of the November 28 session will be available

Settles claims associated with product communications issued by Guidant Corporation in 2005 and 2006; Company acquired Guidant last year

Integration links LATITUDE® Patient Management system to GE's Electronic Medical Record (EMR) system

Getinge Group, a global provider of healthcare equipment and systems, to buy the two businesses for cash price of $750 million

Company believes the finding of patent infringement is in error and will request the judge to overturn it

Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company

Studies evaluated the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease

TAXUS IV study demonstrates long-term safety and efficacy of TAXUS drug- eluting stent compared to bare-metal stent

TAXUS ATLAS studies also reinforce deliverability of TAXUS® Liberte® drug-eluting stent in long lesions and small vessels

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease

Data showed continued low incidences of adverse events and repeat revascularization through two years in complex patients

"The quarter represented a turn for us, with a number of positive developments," said Jim Tobin, President and Chief Executive Officer

Approximately 2,300 positions to be eliminated worldwide

Schedule of Company events for the Cardiovascular Research Foundation's (CRF) 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium